Senazodan |
カタログ番号GC32526 |
セナゾダン (MCI 154) は Ca2+ 増感剤であり、PDE III に対しても阻害効果を示します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 98326-32-0
Sample solution is provided at 25 µL, 10mM.
Senazodan is a Ca2+ sensitiser, and also shows inhibition effect on PDE III.
Senazodan seems to affect directly the actin-myosin crossbridge kinetics, and increase myosin ATPase activity[1]. Senazodan produces a concentration-dependent increase in tension development. Senazodan enhance Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III[2].
[1]. Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. [2]. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70.
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *